118 related articles for article (PubMed ID: 9084795)
21. Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies.
Maguire M; Gartland M; Moore S; Hill A; Tisdale M; Harrigan R; Kleim JP
AIDS; 2000 Jun; 14(9):1195-201. PubMed ID: 10894284
[TBL] [Abstract][Full Text] [Related]
22. Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio.
Martínez E; Ribera E; Clotet B; Estrada V; Sanz J; Berenguer J; Rubio R; Pulido F; Larrousse M; Curran A; Negredo E; Arterburn S; Ferrer P; Álvarez ML
HIV Med; 2015 Jul; 16(6):370-4. PubMed ID: 25496141
[TBL] [Abstract][Full Text] [Related]
23. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.
Kuritzkes DR; Bassett RL; Johnson VA; Marschner IC; Eron JJ; Sommadossi JP; Acosta EP; Murphy RL; Fife K; Wood K; Bell D; Martinez A; Pettinelli CB
AIDS; 2000 Jul; 14(11):1553-61. PubMed ID: 10983642
[TBL] [Abstract][Full Text] [Related]
24. Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand.
European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord
Eur J Clin Pharmacol; 2017 Apr; 73(4):463-468. PubMed ID: 28028587
[TBL] [Abstract][Full Text] [Related]
25. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
26. Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine.
Rower JE; Meditz A; Gardner EM; Lichtenstein K; Predhomme J; Bushman LR; Klein B; Zheng JH; Mawhinney S; Anderson PL
Antimicrob Agents Chemother; 2012 Jun; 56(6):3011-9. PubMed ID: 22391541
[TBL] [Abstract][Full Text] [Related]
27. HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study.
;
AIDS; 1999 Jan; 13(1):57-65. PubMed ID: 10207545
[TBL] [Abstract][Full Text] [Related]
28. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
Sölder B; Wintergerst U; Notheis G; Eberle J; Gürtler L; Belohradsky BH
J Pediatr; 1997 Feb; 130(2):293-9. PubMed ID: 9042135
[TBL] [Abstract][Full Text] [Related]
29. Size and duration of zidovudine benefit in 1003 HIV-infected patients: U.S. Army, Navy, and Air Force natural history data. Military Medical Consortium for Applied Retroviral Research.
Gardner LI; Harrison SH; Hendrix CW; Blatt SP; Wagner KF; Chung RC; Harris RW; Cohn DL; Burke DS; Mayers DL
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr; 17(4):345-53. PubMed ID: 9525436
[TBL] [Abstract][Full Text] [Related]
30. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.
AIDS; 1999 Apr; 13(5):565-73. PubMed ID: 10203381
[TBL] [Abstract][Full Text] [Related]
31. The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children.
Moolasart P; Likanonsakul S
Southeast Asian J Trop Med Public Health; 2002 Jun; 33(2):280-7. PubMed ID: 12236426
[TBL] [Abstract][Full Text] [Related]
32. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC;
AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047
[TBL] [Abstract][Full Text] [Related]
33. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Bravenboer B; Ten Kate RW; Groeneveld P; Bierman W; van der Werf Ts; Gisolf E; Richter C
HIV Med; 2015 Feb; 16(2):122-31. PubMed ID: 25472825
[TBL] [Abstract][Full Text] [Related]
34. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P
AIDS; 2003 Sep; 17(13):1889-96. PubMed ID: 12960821
[TBL] [Abstract][Full Text] [Related]
35. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission.
Dabis F; Bequet L; Ekouevi DK; Viho I; Rouet F; Horo A; Sakarovitch C; Becquet R; Fassinou P; Dequae-Merchadou L; Welffens-Ekra C; Rouzioux C; Leroy V;
AIDS; 2005 Feb; 19(3):309-18. PubMed ID: 15718842
[TBL] [Abstract][Full Text] [Related]
36. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group.
Revicki DA; Moyle G; Stellbrink HJ; Barker C
AIDS; 1999 May; 13(7):851-8. PubMed ID: 10357386
[TBL] [Abstract][Full Text] [Related]
37. Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.
Feeney ER; van Vonderen MG; Wit F; Danner SA; van Agtmael MA; Villarroya F; Domingo P; Capeau J; Reiss P; Mallon PW;
AIDS; 2012 Nov; 26(17):2165-74. PubMed ID: 22874517
[TBL] [Abstract][Full Text] [Related]
38. Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 x 10(6)/L: results of the Zidon trial. Zidon Study Group.
Fernández-Cruz E; Lang JM; Frissen J; Furner V; Châteauvert M; Boucher CA; Dowd P; Stevens J
AIDS; 1995 Sep; 9(9):1025-35. PubMed ID: 8527074
[TBL] [Abstract][Full Text] [Related]
39. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E;
Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872
[TBL] [Abstract][Full Text] [Related]
40. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.
Winston A; McAllister J; Amin J; Cooper DA; Carr A
HIV Med; 2005 May; 6(3):191-7. PubMed ID: 15876286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
